TABLE 39A LIST OF PUBLICATIONS REFERRED TO IN THE ...

2006;32:407-10.
4B.29 Yu-Wai-Man P et al. Efficacy of intracameral and subconjunctival cefuroxime in preventing endophthalmitis
after cataract surgery. J Cataract Refract Surg 2008;34:447-51.
4B.30 Yeh S et al. Current trends in the management of intraocular foreign bodies. Curr Opin Ophthalmol
2008;19:225-33.
4B.31 Marculescu CE et al. Antibiotic prophylaxis in orthopedic prosthetic surgery. Infect Dis Clin North
Am 2005;19:931-46.
4B.32 van Kasteren ME et al. Antibiotic prophylaxis and the risk of surgical site infections following total hip
arthroplasty: timely administration is the most important factor. Clin Infect Dis 2007;44:921-7.
4B.33 Solomkin JS et al. Diagnosis and management of complicated intra-abdominal infection in adults and
children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America.
Clin Infect Dis 2010;50:133-64.
4B.34 Bootsma AM et al. Antibiotic prophylaxis in urologic procedures: a systematic review. Eur Urol 2008;
54:1270-86.
4B.35 Wolf JS et al. Best practice policy statement on urologic surgery antimicrobial prophylaxis. J Urol
2008;178:1379-90.
4C.1 Wilson W et al. Prevention of infective endocarditis. Guidelines of the American Heart Association
Rheumatic Fever, Endocarditis and Kawasaki Disease Committee, Council on Cardiovascular Disease
in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia,
and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation
2007;116:1736-54.
4C.2 Nishimura RA et al. ACC/AHA 2008 guideline update on valvular heart disease: focused update on
infective endocarditis. A report of the American College of Cardiology/American Heart Association
Task Force on Practice Guidelines. Circulation 2008;118:887-96.
4C.3 Shanson D. New British and American guidelines for the antibiotic prophylaxis of infective endocarditis:
do the changes make sense? A critical review. Curr Opin Infect Dis 2008;21:191-9.
4C.4 Habib G et al. Guidelines on the prevention, diagnosis, and treatment of infective endocarditis (new
version 2009). Eur Heart J 2009;30:2369-413.
4D.1 Kabura L et al. Intrathecal vs. intramuscular administration of human antitetanus immunoglobulin or
equine tetanus antitoxin in the treatment of tetanus: a meta-analysis. Trop Med Int Health 2006;11:
1075-81.
4D.2 Brook I. Current concepts in the management of Clostridum tetani infection. Expert Rev Anti Infect
Ther 2008;6:327-36.
5A.1 Pai MP et al. Antimicrobial dosing considerations in obese adult patients: insights from the Society of
Infectious Diseases Pharmacists. Pharmacotherapy 2007;27:1081-91.
5A.2 Erstad BL. Dosing of medications in morbidly obese patients in the intensive care setting. Intensive
Care Med 2004:30:18-32.
5A.3 Wurtz R et al. Antimicrobial dosing in obese patients. Clin Infect Dis 1997;25:112-8.
5A.4 Falagas ME et al. Adjustment of dosing of antimicrobial agents for bodyweight in adults. Lancet
2010;375:248-51.
5A.5 Udy AA et al. Augmented renal clearance: implications for antibacterial dosing in the critically ill. Clin
Pharmacokinet 2010;49:1-16.
5A.6 Stalam M et al. Antibiotic agents in the elderly. Infect Dis Clin North Am 2004;18:533-49.
5A.7 Segal AR et al. Cutaneous reactions to drugs in children. Pediatrics 2007;120:e1082-96.
5A.8 Kaye D. Current use for old antibacterial agents: polymyxins, rifampin, and aminoglycosides. Infect
Dis Clin North Am 2004;18:669-89.
5A.9 Turnidge J. Pharmacodynamics and dosing of aminoglycosides. Infect Dis Clin North Am 2003;17:
503-28.
5A.10 Drusano GL et al. Back to the future: using aminoglycosides again and how to dose them optimally.
Clin Infect Dis 2007;45:753-60.
5A.11 Leibovici L et al. Aminoglycoside drugs in clinical practice: an evidence-based approach. J Antimicrob
Chemother 2009;63:246-51.
5A.12 Jacobs MR. Extended release amoxicillin/clavulanate: optimizing a product for respiratory infections
based on pharmacodynamic principles. Expert Rev Anti Infect Ther 2005;3:353-60.
5A.13 Martin SI et al. Beta-lactam antibiotics: newer formulations and newer agents. Infect Dis Clin North
Am 2004:18:603-19.
5A.14 Maertens J et al. False positive Aspergillus galactomannan antigen test results. Clin Infect Dis 2004;
39:289-90.
5A.15 Hoorn EJ et al. Severe hypokalaemia caused by flucloxacillin. J Antimicrob Chemother 2008;61:
1396-8.
5A.16 Lodise TP et al. Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications
of an extended-infusion dosing strategy. Clin Infect Dis 2007;44:357-63.
5A.17 Gin A et al. Piperacillin-tazobactam: a β-lactam/β-lactamase inhibitor combination. Expert Rev Anti
In-fect Ther 2007;5:365-83.
5A.18 Viscoli C et al. False positive galactomannan Platelia Aspergillus test results for patients receiving piperacillin-tazobactam.
Clin Infect Dis 2004;38:913-6.
5A.19 Adam O et al. Treatment with piperacillin-tazobactam and false positive Aspergillus galactomannan
antigen test results for patients with hematological malignancies. Clin Infect Dis 2004;38:917-20.
5A.20 Maertens J et al. False positive Aspergillus galactomannan antigen test results. Clin Infect Dis 2004;
39:289-90.
5A.21 Walsh TJ et al. Detection of galactomannan antigenemia in patients receiving piperacillin-tazobactam
and correlations between in vitro, in vivo and clinical properties of the drug antigen interaction. J Clin
Microbiol 2004;42:4744-8.
5A.22 Peralta FG et al. Incidence of neutropenia during treatment of bone related infections with piperacillintazobactam.
Clin Infect Dis 2003;37:1568-72.
5A.23 Livermore DM et al. Temocillin revived. J Antimicrob Chemother 2009;63:243-5.
5A.24 De Jongh R et al. Continuous versus intermittent infusion of temocillin, a directed spectrum penicillin